GlassScriptPhysician profile
Michael J Hernandez
NPI 1609927862
$152,513.28
in general payments reported to CMS, 2019-2025
60 companies · $26K in 2025
The $26K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $8,053 · 2021: $23K · 2022: $25K · 2023: $29K · 2024: $29K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $66K · Food and Beverage: $15K · Consulting Fee: $2,108 · Travel and Lodging: $814 · Education: $163 · Gift: $17.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $65,975.00 |
| Food and Beverage | $14,978.22 |
| Consulting Fee | $2,108.00 |
| Travel and Lodging | $813.86 |
| Education | $163.36 |
| Gift | $17.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $113,254.74 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10,090.62 | 2019-2025 | Ofev, Jascayd, Spiriva |
| Intuitive Surgical, INC. | $4,960.20 | 2019-2025 | Da Vinci Surgical System |
| Pulmonx Corporation | $4,046.89 | 2019-2021 | |
| Genzyme Corporation | $3,671.65 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,900.42 | 2019-2025 | Breztri, Fasenra, Airsupra |
| Actelion Pharmaceuticals US, INC. | $2,002.71 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Insmed, INC. | $1,119.07 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $1,115.14 | 2020-2025 | Tyvaso, Tyvaso |
| Advanced Bionics, LLC | $846.07 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $838.99 | 2019-2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $797.26 | 2021-2025 | Acthar |
| Ethicon INC. | $615.82 | 2019-2025 | Monarch Platform |
| Amgen INC. | $559.70 | 2022-2025 | Tezspire |
| Baxter Healthcare | $479.56 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System, Hillrom - Volara System |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $458.79 | 2019-2023 | Xolair |
| Bayer Healthcare Pharmaceuticals INC. | $430.14 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $420.65 | 2020-2025 | Glassia |
| Mylan Specialty L.P. | $416.78 | 2019-2024 | Yupelri |
| Inspire Medical Systems, INC. | $414.54 | 2021-2024 | Inspire |
| Ani Pharmaceuticals, INC. | $375.81 | 2023-2025 | Purified Cortrophin Gel |
| Merck Sharp & Dohme LLC | $248.30 | 2019-2025 | Winrevair |
| Philips North America LLC | $209.87 | 2021-2025 | Vest Therapy Und |
| Novartis Pharmaceuticals Corporation | $191.13 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $168.81 | 2020-2025 | |
| Mallinckrodt Enterprises LLC | $151.54 | 2019 | |
| Electromed, INC. | $134.57 | 2019-2025 | Smartvest |
| Verona Pharma, INC. | $126.54 | 2025 | Ohtuvayre |
| Pfizer INC. | $108.97 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $96.42 | 2021-2024 | Nuzyra |
| Sunovion Pharmaceuticals INC. | $94.30 | 2019-2020 | |
| Circassia INC. | $85.86 | 2019-2020 | |
| Grifols USA, LLC | $83.35 | 2022-2023 | Prolastin-C Liquid |
| Itamar Medical INC | $80.90 | 2022-2023 | Watchpatone |
| Advanced Respiratory, INC | $75.48 | 2019-2021 | |
| Gilead Sciences, INC. | $74.81 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $63.14 | 2020-2022 | |
| Medtronic, INC. | $51.58 | 2023-2024 | Illumisite |
| Viatris Specialty LLC | $50.56 | 2025 | Yupelri |
| Nabriva Therapeutics, Plc | $50.50 | 2021-2022 | |
| Boston Scientific Corporation | $48.67 | 2020-2021 | |
| Lilly USA, LLC | $48.52 | 2025 | Zepbound, Mounjaro |
| Teva Pharmaceuticals USA, INC. | $45.11 | 2020-2025 | Uzedy |
| Resmed Corp | $40.30 | 2023-2024 | |
| Ambu INC. | $37.38 | 2021-2024 | |
| Hikma Pharmaceuticals USA | $32.49 | 2023-2025 | Ryaltris |
| Inogen, INC. | $31.56 | 2024 | |
| Intra-Sana Laboratories | $27.89 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Vifor Pharma, INC. | $26.01 | 2024 | Zemaira |
| Astellas Pharma US INC | $24.91 | 2023 | Cresemba |
| Abbvie INC. | $23.31 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $22.91 | 2024 | |
| Fisher & Paykel Healthcare INC | $22.76 | 2024 | Fisher & Paykel Healthcare |
| Azurity Pharmaceuticals, INC. | $22.68 | 2025 | Alvesco |
| Vapotherm INC | $22.16 | 2022 | |
| Optinose US, INC. | $19.85 | 2024 | |
| Cmp Pharma, INC. | $19.77 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.41 | 2021 | |
| Phadia US INC. | $16.41 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hernandez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.